U.S. FDA files import alert on India's Pan Drugs

The U.S. Food and Drug Administration said violations of manufacturing protocols at Pan Drugs forced it to issue an "import alert" for human and animal medicines made by the Indian company.

The FDA said the company violated Good Manufacturing Practices (GMP) and the alert will allow the FDA to detain the drugs without examining them.

This is just the latest blow to Pan Drugs, based in Vadodara in Gujarat state, which suffered after the FDA in May blocked the company's exports to the United States for the same reasons. The FDA warned the company in September that it still faced an import alert because despite the company pledging to fix its facilities, it still was not in compliance.

The company was also criticized for diverting the faulty drugs to the Indian market, a move that raised questions about Indian enforcement of quality control regulations.

- here's the story from the Economic Times

Suggested Articles

New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

A decree includes tax incentives for certain generic drugmakers and uniform insurance standards that apply to both branded drugs and generics.